Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes
Abbott announced that both the XIENCE PRIME™ Everolimus Eluting Coronary Stent System(1) and the XIENCE V® Everolimus Eluting Coronary Stent System have received additional new CE Markings (Conformité Européenne) covering the treatment of patients with diabetes. Receiving these new indications among the European Union Member States validates the use of XIENCE PRIME and XIENCE V to treat patients with diabetes. 
Merck & Co., Inc. (NYSE: MRK) outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.
Novartis announced a USD 1 billion investment over the next five years, increasing R&D activities in China and confirming Novartis' long term commitment to China's further economic development, health reform and improving the health care of the Chinese people. The Novartis investment will include a significant expansion of The Novartis Institute of BioMedical Research (CNIBR) in Shanghai.
Professor Steven V. Ley of the Cambridge University (UK) was awarded this year's Heinrich Wieland Prize in appreciation of his extraordinary scientific achievements in the fields of synthesis, structural analysis and biological characterization of natural products. The award endowed with EUR 50,000 was given to him at the Ludwig Maximilian University of Munich. 
Revenue in the third quarter increased by 10 percent at CER, but was up 5 percent on an actual basis as a result of the negative impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); adjusting for these factors, global revenue increased by 5 percent. 
Sales increased by 15% in Danish kroner and by 11% in local currencies: